Mortality benefit from unrestricted access to clopidogrel: too good to be true?
作者信息
Suissa Samy
机构信息
Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre and the Department of Epidemiology and Biostatistics, McGill University, Montréal, Que.
出版信息
CMAJ. 2008 Feb 12;178(4):425-7. doi: 10.1503/cmaj.071592.
Abstract
摘要
相似文献
1
Mortality benefit from unrestricted access to clopidogrel: too good to be true?
CMAJ. 2008 Feb 12;178(4):425-7. doi: 10.1503/cmaj.071592.
2
Restrictive access to clopidogrel and mortality following coronary stent implantation.
CMAJ. 2008 Feb 12;178(4):413-20. doi: 10.1503/cmaj.070586.
3
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent.
Am J Health Syst Pharm. 2007 Jul 1;64(13):1432-4. doi: 10.2146/ajhp070084.
4
Is prasugrel more effective than clopidogrel at preventing future cardiac events?
JAAPA. 2011 Feb;24(2):52, 55. doi: 10.1097/01720610-201102000-00010.
5
Risk and benefit of proton pump inhibitor for patients undergoing anti-platelet therapy including clopidogrel.
Intern Med. 2009;48(21):1847-8. doi: 10.2169/internalmedicine.48.2709. Epub 2009 Nov 2.
6
[General antithrombotic therapy practice facing fundamental change].
MMW Fortschr Med. 2012 Sep 10;154(15):24. doi: 10.1007/s15006-012-1054-7.
7
Is it naive to load only clopidogrel-naive patients prior to PCI?
Eur Heart J. 2010 Jun;31(11):1298-300. doi: 10.1093/eurheartj/ehq082. Epub 2010 Apr 2.
8
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
Coron Artery Dis. 2004 Sep;15(6):347-52. doi: 10.1097/00019501-200409000-00008.
9
10
Regarding comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy: problems with listing patients receiving clopidogrel for re-transplantation.
JACC Cardiovasc Interv. 2009 May;2(5):474; author reply 474-5. doi: 10.1016/j.jcin.2009.02.013.
本文引用的文献
1
Restrictive access to clopidogrel and mortality following coronary stent implantation.
CMAJ. 2008 Feb 12;178(4):413-20. doi: 10.1503/cmaj.070586.
2
Immortal time bias in observational studies of drug effects.
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9. doi: 10.1002/pds.1357.
3
Clopidogrel and percutaneous coronary interventions.
JAMA. 2003 Apr 16;289(15):1925; author reply 1926-7. doi: 10.1001/jama.289.15.1925-a.
4
Clopidogrel and percutaneous coronary interventions.
JAMA. 2003 Apr 16;289(15):1925-6; author reply 1926-7. doi: 10.1001/jama.289.15.1925-b.
5
Clopidogrel and percutaneous coronary intervention.
Lancet. 2002 Jan 12;359(9301):169. doi: 10.1016/S0140-6736(02)07351-8.
Zotero 插件